Advertisement
Canada markets closed
  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    87,317.55
    -1,161.35 (-1.31%)
     
  • CMC Crypto 200

    1,331.69
    -64.85 (-4.64%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     
  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Company News For Jun 19, 2018

MEET vs. WDAY: Which Stock Is the Better Value Option?
  • JD.com, Inc.’s JD shares increased 0.4% on news that Alphabet, Inc. GOOGL was making an investment of $550 million in the Chinese e-commerce giant.

  • Shares of Valeant Pharmaceuticals International, Inc. VRX declined 12.3% after one of its lotions intended to treat plaque psoriasis failed to earn approval from the Food and Drug Administration.

  • Solid Biosciences Inc.’s SLDB shares jumped 10.9% after the company announced that the Food and Drug Administration had lifted the clinical hold on its treatment for Duchenne muscular dystrophy

  • Shares of Tesla, Inc. TSLA rose 3.5% after its CEO Elon Mask unveiled the company’s new production line in a tweet over the weekend


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JD.com, Inc. (JD) : Free Stock Analysis Report
 
Alphabet Inc. (GOOGL) : Free Stock Analysis Report
 
Tesla, Inc. (TSLA) : Free Stock Analysis Report
 
Valeant Pharmaceuticals International, Inc. (VRX) : Free Stock Analysis Report
 
Solid Biosciences Inc. (SLDB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research